CTOs on the Move

Renalytix

www.renalytix.com

 
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.renalytix.com
  • 101 Avenue of the Americas Suite 324
    New York, NY USA 10013
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.

PowerMedica

PowerMedica is a Deerfield Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genome British Columbia

Genome British Columbia is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

On Target Laboratories

Our illuminating molecules enhances the doctors ability to see disease tissue clearly improving their ability to treat cancer, autoimmune and other diseases.

GABA Therapeutics,

A New Dawn for Central Nervous System Treatments GABA Therapeutics is developing GRX-917, an anxiety medication as effective as benzodiazepines like Xanax, but with minimal to no side effects. The drugs dual mechanism of action may also benefit ...